安帝君斯 AGEN 深 沪
已收盘 07-02 16:00:00 美东时间
3.49
+0.080
+2.35%
华盛通- 最 高3.515
- 今 开3.40
- 成交量 68.06万股
- 最 低 3.37
- 昨 收 3.41
- 总市值 1.45亿
- 52周最高 7.04
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 2.71
- 委 比 54.82%
- 总股本 4164.24万
- 历史最高 202.5868
- 量 比 0.43
- 振 幅 4.25%
- 历史最低 1.38
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agenus shareholders approve 5 million-share increase to 2019 equity plan at annual meeting
Agenus shareholders approve 5 million-share increase to 2019 equity plan at annual meeting Agenus held its annual shareholder meeting on June 16, 2026. Shareholders backed amendments to the 2019 Employee Stock Purchase Plan, lifting the share pool to 200,000 from 150,000. An amendment to the Amended
06-23 22:14
Agenus Announces Resignation of Principal Accounting Officer
Agenus ( ($AGEN) ) has shared an update. On May 12, 2026, Agenus Inc. disclosed...
05-16 04:32
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapyMedian overall survival of 12.3 months in a heavily pretreated population with poor prognostic
05-16 04:16
Agenus shares are trading lower. The company reported its Q1 financial results.
Agenus shares are trading lower. The company reported its Q1 financial results.
05-12 00:41
Agenus reports Q1 results
Agenus press release (AGEN): Q1 Cash and cash equivalents totaled $35.0 million as of March 31, 2026, compared with $3.0 million as of December 31, 2025. The company also expects to collect outstandi...
05-11 20:54
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit Overview US immuno-oncology developer's Q1 revenue grew yr/yr, driven by BOT+BAL program Company reported positive net income for Q1, compared to loss in prior yr Agenus closed Zydus collaboration, strengthening capital and securing U.
05-11 20:53
Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million
Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million Agenus posted Q1 2026 revenue of USD 33.7 million, including USD 4.6 million in pre-commercial product revenue, while operating income swung to USD 15.1 million. Net income swung to USD 39.2 million, while cash and cas
05-11 20:45
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of heavily
04-18 04:49
Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR
Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR Agenus flagged new Phase II trial data in PD-1 refractory gastroesophageal cancer for future presentation at AACR 2026. Study evaluates botensilimab with balstilimab alongside MiNK Therapeutics’ allogeneic iNKT cel
04-03 19:30
